<?xml version="1.0" encoding="UTF-8"?>
<rss xmlns:content="http://purl.org/rss/1.0/modules/content/" version="2.0">
  <channel>
    <title><![CDATA[Neurodegenerative Disease]]></title>
    <link>https://www.leadingmarketresearch.com/pharmaceuticals-biotechnology/pharmaceuticals/therapeutic-areas/neurodegenerative-disease</link>
    <description><![CDATA[Neurodegenerative Disease]]></description>
    <pubDate>Fri, 10 Apr 2026 18:51:02 +0000</pubDate>
    <generator>Zend_Feed</generator>
    <docs>http://blogs.law.harvard.edu/tech/rss</docs>
    <item>
      <title><![CDATA[Neurodegenerative Disorders Drug Development Pipeline Review, 2017]]></title>
      <link>https://www.leadingmarketresearch.com/neurodegenerative-disorders-drug-development-pipeline-review-2017</link>
      <description><![CDATA[<table><tr><td  style="text-decoration:none;"><p><b>Summary</b><br><br>Neurodegenerative disorders are a cluster of conditions that affect the central nervous system. They include both hereditary and sporadic conditions that are characterized by slow, irreversible, progressive dysfunction of the nervous system with the increasing degeneration of neurons, which causes symptoms such as motor impairment, memory loss and declining cognitive ability. Neurodegenerative disorders cannot currently be cured, and treatment is aimed at managing the disease indication in order to reduce the severity of symptoms and slow progression.<br><br>There are over 1,400 products in active development in the neurodegenerative disorders therapy area. The current market landscape consists of a number of biologics and small molecules, while the pipeline also consists of gene therapies and cell therapies, demonstrating broader pharmaceutical research and development.<br><br>Small molecule drugs dominate the pipeline, with approximately 64% of total pipeline molecules. In comparison, the number of biologics in the pipeline is much lower, representing appro...





        
    <div class="price-box">
                                                            <span class="regular-price" id="product-price-196242"><span class="price">$3,995.00</span></span>
                        
        </div>

</td></tr></table>]]></description>
      <pubDate>Fri, 28 Apr 2017 10:35:57 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Global Neurodegenerative Drugs Market to 2022 - Growth Driven by an Aging Population, the Approval of Novel Immunomodulators and Neuromodulators, and Strong Uptake of Marketed Anti-Inflammatory Treatments]]></title>
      <link>https://www.leadingmarketresearch.com/global-neurodegenerative-drugs-market-to-2022-growth-driven-by-an-aging-p</link>
      <description><![CDATA[<table><tr><td  style="text-decoration:none;"><p><b>Summary</b><br><br>Neurodegenerative disorders are a cluster of conditions that affect the central nervous system. They include both hereditary and sporadic conditions that are characterized by slow, irreversible, progressive dysfunction of the nervous system with the increasing degeneration of neurons, which causes symptoms such as motor impairment, memory loss and declining cognitive ability. Neurodegenerative disorders cannot currently be cured, and treatment is aimed at managing the disease indication in order to reduce the severity of symptoms and slow progression.<br><br>The report focuses on five key indications within neurodegenerative disorders: Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, amyotrophic lateral sclerosis and multiple sclerosis. With no curative therapies available, symptomatic medications prescribed off-label are an important part of the treatment paradigm, especially in amyotrophic lateral sclerosis and multiple sclerosis. This indicates the need for extensive R&D within this area.<br><br>Immunomodulators are the most effective ...





        
    <div class="price-box">
                                                            <span class="regular-price" id="product-price-196243"><span class="price">$4,995.00</span></span>
                        
        </div>

</td></tr></table>]]></description>
      <pubDate>Fri, 28 Apr 2017 10:35:57 +0000</pubDate>
    </item>
  </channel>
</rss>
